IDO1 and neoplasm: Similarly, melanoma patients who were resistant to previous treatment with radiotherapy plus ipilimumab showed increased plasma Kyn/Trp ratio, further confirming that Ido-1 may be activated as escape mechanism to immunotherapy induced anti-tumor response [19].